Skip to Content

Newsroom

Response Rate Promising in Test of C225 and Docetaxel in Advanced Lung Cancer

News Tips on Targeted Therapy Studies Presented at the American Society of Clinical Oncology May 31 – June 3, 2003 Chicago, Ill.

Response Rate Promising in Test of C225 and Docetaxel in Advanced Lung Cancer
M. D. Anderson News Release 05/31/03

Researchers testing a combination of chemotherapy and the experimental monoclonal antibody agent C225 in patients with advanced, relapsed non-small cell lung cancer found that 65% of 47 patients had a response or stable disease, and several patients remain alive almost one year after starting the therapy.

The "encouraging" results merit development of a larger, randomized trial, says the study leader, Edward Kim, M.D., of The University of Texas M. D. Anderson Cancer Center.

The Phase II clinical trial was conducted at M. D. Anderson, the University of Chicago and Arlington Cancer Center.

The study is the only one to test a cocktail of docetaxel chemotherapy and C225 for second-line treatment after patients stop responding to initial chemotherapy. All patients had advanced non-small cell lung cancer that was progressing from their original therapy.

In the study, one patient had a complete response; 11 patients had a confirmed partial response (tumor shrinkage that lasted at least several months and was verified using a diagnostic CAT scan); one patient had an unconfirmed partial response (this patient died of unrelated causes before the response could be verified); and 18 patients had disease stabilization. Five patients still remain on the study, some of whom have been treated with more than 20 tri-weekly cycles of C225.

By the most conservative estimate, this means tumors shrank in one-quarter (25.5%) of patients in this trial, whereas median response in second-line therapy is generally 5% to10%, according to Kim, an assistant professor in the Department of Thoracic/Head and Neck Medical Oncology. That response is not likely due to the use of docetaxel, given that a large Phase III trial of this docetaxel as second line therapy found a response rate of just 6 %.

"This is not a home run, but the results are promising," he says. "This is the best response rate we have seen in combination, second-line therapy for this advanced cancer."

 C225, an experimental biological treatment that blocks EGF and other molecules that promote growth from sticking to the surface of cancer cells and tumors, is being tested in other cancers, including colon and head and neck malignancies. Docetaxel is currently approved for treatment of various cancers including lung cancer and breast cancer.

05/31/03


© 2014 The University of Texas MD Anderson Cancer Center